Plasma glycooxidation protein products in type 2 diabetic patients with nephropathy

Piwowar, Agnieszka; Knapik-Kordecka, Maria; Szczecińska, Joanna; Warwas, Maria

doi:10.1002/dmrr.885

Cited by 33 publications

(31 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma was initially analysed using a previously published AOPP method [8–10, 12, 17]. Of the 77 plasma samples assessed from both diabetic patients and nondiabetic control subjects, only 27 produced an interreplicate CV of less than 20%, and only six of these were under 10% (see Supplementary Material 1 available online at http://dx.doi.org/10.1155/2015/496271).…”

Section: Resultsmentioning

confidence: 99%

“…Some studies have found that AOPP are moderately elevated in adult patients with Type 1 diabetes and more markedly elevated in those with Type 2 diabetes [8, 9], although others have suggested that AOPP are only significantly increased in Type 2 diabetes [10]. They have been reported to be elevated in Type 2 diabetes [11], and the concentration correlated with insulin resistance [12] or the presence and/or severity of diabetic complications [13, 14], such as retinopathy [15, 16] or nephropathy [17]. In juveniles and adolescents with Type 1 diabetes, AOPP were found to accumulate over time and were significantly associated with disease duration [18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Optimisation of an Advanced Oxidation Protein Products Assay: Its Application to Studies of Oxidative Stress in Diabetes Mellitus

Taylor

Armstrong

Perrett

et al. 2015

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Advanced oxidation protein products (AOPP) are reportedly elevated in the plasma of patients with a number of diseases, including diabetes mellitus, that involve oxidative stress. However, the accurate measurement of AOPP in human plasma is hampered by the formation of a precipitate following the addition of potassium iodide and glacial acetic acid according to the published assay procedure. Here we describe a modification of the AOPP assay which eliminates interference by precipitation and provides a robust, reliable, and reproducible protocol for the measurement of iodide oxidising capacity in plasma samples (intra-assay CV 1.7–5.3%, interassay CV 5.3–10.5%). The improved method revealed a significant association of AOPP levels with age (p < 0.05) and hypertension (p = 0.01) in EDTA-anticoagulated plasma samples from 52 patients with diabetes and 38 nondiabetic control subjects, suggesting a possible link between plasma oxidising capacity and endothelial and/or vascular dysfunction. There was no significant difference between AOPP concentrations in diabetic (74.8 ± 7.2 μM chloramine T equivalents) and nondiabetic (75.5 ± 7.0 μM chloramine T equivalents) individuals.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Optimisation of an Advanced Oxidation Protein Products Assay: Its Application to Studies of Oxidative Stress in Diabetes Mellitus

Taylor

Armstrong

Perrett

et al. 2015

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…In the literature, it has been reported that MDA levels have increased in type 2 DM. 9 However, there are many hypotheses about the possible mechanisms involved in lipid peroxidation increase such as hypercholesterolemia, 34 hypertriglyceridaemia, 22 and the formation of AGEs. 35 Similar to the study of Komosinska et al, 36 we also found a significantly positive correlation between MDA levels and HbA 1c concentration, which suggests that hyperglycemia could also be a probable mechanism involved in the increased MDA levels, in type 2 DM patients.…”

Section: Discussionmentioning

confidence: 99%

Association among Microalbuminuria and Oxidative Stress Biomarkers in Patients with Type 2 Diabetes

Vicentini

Valentini

Grotto

et al. 2011

Journal of Investigative Medicine

View full text Add to dashboard Cite

The hyperglycemia could be responsible for the increase of the microalbuminuria levels and for the oxidation process in lipids and proteins in DM patients. Therefore, we suggested that the microvascular lesion is a direct consequence from hyperglycemia and an indirect one from the increased oxidative stress. Malondialdehyde and protein carbonyl levels could be suggested as additional biochemical evaluation to verify tissue damage in type 2 DM patients.

show abstract

“…9,16 AOPP levels was related with poor glycaemic control, obesity, lipid disorders, duration of disease (longer than 10 years), and diabetic complications including nephropathy. 4,16,17 IMA levels were also higher in diabetic patients, especially those with complications, and was related to the levels of HbA1c. 9 In diabetes, the most frequent complication is diabetic nephropathy (DN), which is the most common cause of end-stage renal disease, requiring dialysis, and it shortens human life.…”

mentioning

confidence: 90%

Comparison of the usefulness of plasma levels of oxidatively modified forms of albumin in estimating kidney dysfunction in diabetic patients

Piwowar¹,

Knapik-Kordecka²,

Warwas³

2010

CIM

Self Cite

View full text Add to dashboard Cite

Clin Invest Med 2010; 33 (2): E109-E116. AbstractPurpose: Advanced oxidation protein products (AOPP) and ischemia-modified albumin (IMA) are forms of oxidatidatively modified albumin and have recently been investigated as indicators of oxidative stress. They are increased in different disorders, including diabetes mellitus, as a result of hyperglycaemia, oxidative stress and hypoxia. The usefulness of the plasma levels of these two parameters in estimating kidney dysfunction in type 2 diabetic patients (T2DM) was compared in this study. Methods: Plasma levels of AOPP and IMA were determined spectrophotometrically in 218 individuals, 153 patients with T2DM and 65 healthy people.. The urinary albumin/creatinine ratio (UACR) was used as the reference to define the stage of kidney dysfunction by the assessment of the degree of albuminuria. Results: Receiver Operating Characteristic (ROC) curve analysis, likelihood ratio (LR), and Youden's index (J) revealed that AOPP and IMA had acceptable sensitivities and specificities in individuals with different degrees of albuminuria; however, AOPP had higher values of the area under the curve (AUC: 0.934) than IMA, as well as 100% sensitivity and 77.01% specificity for distinguishing patients with micro-and macroalbuminuria. Conclusions: Both AOPP and IMA may be helpful clinical markers for estimating kidney dysfunction, but AOPP is better able to identify diabetic patients with nephropathy. We suggest that AOPP is almost ideal for discriminating between T2DM patients with micro-and macroalbuminuria.In the plasma of diabetic patients, the albumin molecule is modified under conditions of chronic hypoxia, provoked mainly by the hyperglycaemia and oxidative stress (OS) existing in these patients. This leads to many changes in the structure and function of albumin including the formation of advanced oxidation protein products (AOPP) and ischemia-modified albumin (IMA). 1-4 AOPP were first detected in uremic and haemodialysed patients. They are formed during OS by the action of free radicals, mainly chloraminated oxidants (hypochlorous acid and chloramines) produced by myeloperoxidase in activated neutrophils. This leads to the formation of dityrosine residues and protein cross-linking, which results in abnormal albumin molecules in the plasma. AOPP are recognized as very good markers of oxidative damage to proteins and as indicators of disturbances in the oxidant/ antioxidant balance. 3,5,6 IMA is an albumin molecule modified by hypoxic conditions, which causes a ORIGINAL RESEARCH

show abstract

Plasma glycooxidation protein products in type 2 diabetic patients with nephropathy

Cited by 33 publications

References 31 publications

Optimisation of an Advanced Oxidation Protein Products Assay: Its Application to Studies of Oxidative Stress in Diabetes Mellitus

Optimisation of an Advanced Oxidation Protein Products Assay: Its Application to Studies of Oxidative Stress in Diabetes Mellitus

Association among Microalbuminuria and Oxidative Stress Biomarkers in Patients with Type 2 Diabetes

Comparison of the usefulness of plasma levels of oxidatively modified forms of albumin in estimating kidney dysfunction in diabetic patients

Contact Info

Product

Resources

About